Status:
UNKNOWN
The Effects of Calcitriol on Biomarkers in Diabetic Kidney Disease Patients
Lead Sponsor:
Indonesia University
Conditions:
Diabetic Kidney Disease
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Diabetic Kidney Disease (DKD) is a complication that occurs due to poor glycemic control over a long period. The decrease or loss of podocytes is an important index in determining the degree of glomer...
Detailed Description
Diabetic Kidney Disease (DKD) is a complication that occurs due to poor glycemic control over a long period. The decrease or loss of podocytes is an important index in determining the degree of glomer...
Eligibility Criteria
Inclusion
- Controlled type 2 diabetes mellitus with HbA1C at least \<8% and albuminuria (UACR\>30 mg/mmol)
- Estimated Glomerular Filtration Rate (eGFR) \>45 ml/min/1.73 m2
- Agree to participate in the research
Exclusion
- Uncontrolled hypertension with routine Angiotensin-converting-enzyme inhibitors (ACEi) or Angiotensin II receptor blockers (ARBs) treatment
- Hypercalcemia (total serum Ca level \>10/5 mg/dL)
- Hyperphosphatemia (total serum phosphate level \>5 mg/dL)
- Hypersensitivity to calcitriol
- Suffering from other diseases that cause proteinuria
- Acute diseases
- Smoker or previous smoking history
- Taking medications or suplements that can affect calcitriol metabolism (thiazide, digoxin, anti-convulsant)
Key Trial Info
Start Date :
April 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2022
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT05298163
Start Date
April 1 2022
End Date
December 1 2022
Last Update
April 6 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dr. Cipto Mangunkusumo Hospital
Jakarta Pusat, DKI Jakarta, Indonesia, 10430